Moreover Technologies - Biotech news - 30 of 9376 returned

Acai Berry SHOCKER (Health News 6) - Sponsored Link

Wed, 10 Feb 2010 04:18:00 GMT

Ad - Will Acai Berry Really Help You Lose Fat? Read Our Special Report

Mansell Promoted to Manager, U.S. Fleet Services for Amgen USA

Wed, 10 Feb 2010 04:18:00 GMT

THOUSAND OAKS, CA - Amgen USA, Inc. has promoted Marilyn Mansell to manager, U.S. Fleet Services, based in Thousand Oaks, Calif. In her new role, Mansell is responsible for fleet management and fleet safety for the company's U.S. fleet. Previously,

Amgen's denosumab offers hope in rare bone tumours

Wed, 10 Feb 2010 03:46:00 GMT

* Small trial offers hope for giant-cell tumour patients * Data add to other positive results for denosumab LONDON, Feb 10 - Amgen's AMGN.O bone drug denosumab stops progressive bone destruction and tumour spread in some patients with a rare type of

Biogen Beats & Guides Higher

Wed, 10 Feb 2010 03:37:00 GMT

Biogen Idec Inc. (BIIB - Performance was driven by higher revenues and lower expenses. Revenues increased 5% to $1.1 billion, with Tysabri and Avonex being the primary growth drivers. For the full year, the company reported earnings of $4.03, well above

Biogen 4th-qtr profit up; outlook tops estimates

Wed, 10 Feb 2010 03:27:00 GMT

Extract not available.

Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche

Wed, 10 Feb 2010 03:22:00 GMT

BOSTON AND LA JOLLA, CA-- Dana-Farber Cancer Institute and the Sanford-Burnham Medical Research Institute have signed a license agreement with Genentech, a wholly owned member of the Roche group, and Roche, that grants the companies exclusive rights to

Biogen Tops Estimates on Solid Tysabri Sales; Challenges Ahead

Wed, 10 Feb 2010 03:18:00 GMT

Biogen Idec Inc.'s fourth-quarter earnings topped analyst estimates, driven by sales of controversial multiple sclerosis drug Tysabri (natalizumab), but the Cambridge, Mass.-based firm faces challenges ahead as it works to defend its MS franchise from

Activist Investor Pushes Celera to Divest Merck Bone Drug Royalties

Wed, 10 Feb 2010 03:18:00 GMT

The Biotechnology Value Fund (BVF), a historically activist investor group, revealed in a 13-D filing Tuesday the reason for its recent interest in diagnostics firm Celera Corp.: BVF wants Celera to spin out its royalty interest in Merck & Co. Inc.'s

Amgen's denosumab offers hop

Wed, 10 Feb 2010 03:13:00 GMT

Extract not available.

Sequenom gets major licensing agreement

Wed, 10 Feb 2010 03:06:00 GMT

This web site just attempted to open a window, but it was blocked by your pop-up blocker. To see pop-up windows in the O.N.E. Network, you need to add this site to your allowed sites list. Two commonly-used popup blockers are: Google Toolbar Internet

Amgen (AMGN) Appears On Investors Observer Analysts Favorites List

Wed, 10 Feb 2010 03:03:00 GMT

Amgen (NASDAQ: AMGN) closed yesterday at $57.46. So far the stock has hit a 52-week low of $44.96 and 52-week high of $64.76. Amgen stock has been showing support around 56.14 and resistance in the 58.58 range. Technical indicators for the stock are

India says no to first GM food crop

Wed, 10 Feb 2010 02:25:00 GMT

NEW DELHI: India refused to grant permission Wednesday to the commercial cultivation of its first genetically modified (GM) food crop, citing problems of public trust and confidence.In a written statement, Environment Minister Jairam Ramesh said he was

Biogen Idec Reports Full Year and Fourth Quarter 2009 Results

Wed, 10 Feb 2010 02:24:00 GMT

13% Non-GAAP and 26% GAAP Diluted EPS Growth Over Prior Year;TYSABRI In-Market Sales Exceeded $1 Billion CAMBRIDGE, MA, USA I February 09, 2010 I Biogen Idec Inc. (NASDAQ: BIIB), a global biotechnology leader in the discovery, development, manufacturing,

UK Court Affirms Invalidity Of Gene Patent In Lilly Suit

Wed, 10 Feb 2010 02:15:00 GMT

Extract not available.

Cephalon Bullish Moving Average Crossover Alert (CEPH)

Wed, 10 Feb 2010 02:04:00 GMT

Today, shares of Cephalon (NASDAQ:CEPH) have crossed bullishly above their 10-day moving average of $65.27 on volume of 742 thousand shares. This may provide swing traders with an opportunity for a long position as such a crossover often suggests higher

Genzyme Names Ex-Lilly Exec to Head Manufacturing

Wed, 10 Feb 2010 02:04:00 GMT

Extract not available.

XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients

Wed, 10 Feb 2010 02:04:00 GMT

(GlobeNewswire via COMTEX News Network) -- XOMA Ltd. (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, announced that enrollment is underway in a 325-patient Phase 2b dose-ranging clinical trial of its antibody

AIS Introduces a Open Standard PC-Based Process Automation System featuring an Fully Rugged Design and HMI Operator Interface Technology for Industrial, Chemical, Pharmaceutical and Biotech Industries

Wed, 10 Feb 2010 02:03:00 GMT

IRVINE, CA -- American Industrial Systems Inc. (AIS), has introduced a line of Full IP65/NEMA 4 Rated Weatherproof LCD Computers for superior performance in wet, dusty, rugged, and humid environments. Several completely fanless system options are

Gilead's quad pill for AIDS patients may overtake Atripla, COO says

Wed, 10 Feb 2010 01:53:00 GMT

Gilead Sciences, the world's biggest maker of AIDS medicines, will begin three final-stage tests this year for a four-drug combination pill against HIV that has the potential to generate $4 billion a year by 2014. The 'quad' may overtake sales of

Ex Vivo Hepatocyte Gene Therapy: Increased Biosafety Protocol for Transduction in Suspension With Lentiviral Vectors and Immediate Transplantation (SLIT): Erratum

Wed, 10 Feb 2010 01:51:00 GMT

issue of Transplantation, in the article “Ex Vivo Hepatocyte Gene Therapy: Increased Biosafety Protocol for Transduction in Suspension With Lentiviral Vectors and Immediate Transplantation (SLIT)” by Birraux, et al, the authors were listed

Piedmont Triad, N.C., biotech news/ Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease

Wed, 10 Feb 2010 01:38:00 GMT

Triad - WINSTON-SALEM, N.C. - Targacept, Inc. , a clinical-stage biopharmaceutical company developing novel NNR Therapeutics (TM), today announced that it has been awarded a grant of $304,000 from The Michael J. Fox Foundation for Parkinson's Research

BiomedReports: News and FDA Updates for Tianyin (NYSE:TPI), Vyteris (OTC:VYTR), YM BioSciences (NYSE:YM)

Wed, 10 Feb 2010 01:33:00 GMT

(M2 PRESSWIRE via COMTEX News Network) -- BioMedReports. Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and

BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)

Wed, 10 Feb 2010 01:33:00 GMT

BioMedReports. Com, the news portal which covers Wall Street's biomedical sector and delivers financial and investment intelligence to a community of highly informed investors has Healthcare stock news and updates to its calendar database of Clinical

India defers first GM food crop

Wed, 10 Feb 2010 01:07:00 GMT

India has deferred the commercial cultivation of what would have been its first genetically modified vegetable crop due to safety concerns, according to the BBC. Environment Minister Jairam Ramesh said more studies were needed to ensure genetically

Setback for GM crops as India delays launch

Wed, 10 Feb 2010 01:06:00 GMT

INDIA has postponed the launch of its first genetically modified crop amid safety fears. Environment minister Jairam Ramesh said more studies were needed to ensure GM aubergines would not harm consumers and the environment. The crop has undergone trials

Options Hotlist Update â" Options Trading in Clorox (CLX) and Genzyme (GENZ)

Wed, 10 Feb 2010 01:05:00 GMT

Analyzing unusual options trading activity on Clorox (CLX) and Genzyme (GENZ) Steve Claussen is the Chief Investment Strategist for OptionsHouse. His 15-year career in the option and derivatives trading business began on the historic floor of the Chicago

Biotechnology

Wed, 10 Feb 2010 00:58:00 GMT

BIOTECHNOLOGY looks at news relating to biotech companies, their financial performance, licensing, research and merger & acquisition activities. Read wide ranging reports from around the globe, backed by a massive archive from which developments in

Amgen's denosumab offers hope in rare bone tumours

Wed, 10 Feb 2010 00:51:00 GMT

LONDON, Feb 10 (Reuters) - Amgen's bone drug denosumab stops progressive bone destruction and tumour spread in some patients with a rare type of non-malignant bone cancer, according to final data from a small mid-stage trial. The data, the first to

Martek Biosciences Upward Momentum Looks to Continue (MATK) - Zib...

Wed, 10 Feb 2010 00:51:00 GMT

Company: Martek Biosciences Corp. (MATK) SmarTrend identified an Uptrend for Martek Biosciences (NASDAQ:MATK) on December 24, 2009 at $18.75. In approximately 2 months, Martek Biosciences has returned 8.6% as of today's recent price of $20.37. Martek

Martek Biosciences Upward Momentum Looks to Continue (MATK) - Zib...

Wed, 10 Feb 2010 00:50:00 GMT

Amgen's denosumab offers hope in rare bone tumours

Wed, 10 Feb 2010 00:49:00 GMT

* Small trial offers hope for giant-cell tumour patients * Data add to other positive results for denosumab LONDON, Feb 10 (Reuters) - Amgen's bone drug denosumab stops progressive bone destruction and tumour spread in some patients with a rare

Moreover Technologies - Biotech news - 30 of 9376 returned

Acai Berry SHOCKER (Health News 6) - Sponsored Link

Mansell Promoted to Manager, U.S. Fleet Services for Amgen USA

Amgen's denosumab offers hope in rare bone tumours

Biogen Beats & Guides Higher

Biogen 4th-qtr profit up; outlook tops estimates

Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche

Biogen Tops Estimates on Solid Tysabri Sales; Challenges Ahead

Activist Investor Pushes Celera to Divest Merck Bone Drug Royalties

Amgen's denosumab offers hop

Sequenom gets major licensing agreement

Amgen (AMGN) Appears On Investors Observer Analysts Favorites List

India says no to first GM food crop

Biogen Idec Reports Full Year and Fourth Quarter 2009 Results

UK Court Affirms Invalidity Of Gene Patent In Lilly Suit

Cephalon Bullish Moving Average Crossover Alert (CEPH)

Genzyme Names Ex-Lilly Exec to Head Manufacturing

XOMA Initiates Phase 2b Dose-Ranging Clinical Trial of XOMA 052 in Type 2 Diabetes Patients

AIS Introduces a Open Standard PC-Based Process Automation System featuring an Fully Rugged Design and HMI Operator Interface Technology for Industrial, Chemical, Pharmaceutical and Biotech Industries

Gilead's quad pill for AIDS patients may overtake Atripla, COO says

Ex Vivo Hepatocyte Gene Therapy: Increased Biosafety Protocol for Transduction in Suspension With Lentiviral Vectors and Immediate Transplantation (SLIT): Erratum

Piedmont Triad, N.C., biotech news/ Targacept Awarded a Grant from The Michael J. Fox Foundation to Conduct Biomarker Research for Parkinson's Disease

BiomedReports: News and FDA Updates for Tianyin (NYSE:TPI), Vyteris (OTC:VYTR), YM BioSciences (NYSE:YM)

BiomedReports: News and FDA Updates for Synta (NASDAQ:SNTA), Teva (NASDAQ:TEVA), Active Biotech (NASDAQ:ACTI)

India defers first GM food crop

Setback for GM crops as India delays launch

Options Hotlist Update â" Options Trading in Clorox (CLX) and Genzyme (GENZ)

Biotechnology

Amgen's denosumab offers hope in rare bone tumours

Martek Biosciences Upward Momentum Looks to Continue (MATK) - Zib...

Martek Biosciences Upward Momentum Looks to Continue (MATK) - Zib...

Amgen's denosumab offers hope in rare bone tumours

Options Hotlist Update â" Options Trading in Clorox (CLX) and Genzyme (GENZ)